Home » Healthcare » Pharmaceuticals » Pharmacogenomics Market

Pharmacogenomics Market By Technology (Microarray, Sequencing, Polymerase Chain Reaction), By Application (Oncology, Cardiology, Pain Management, Neurological Disorders) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2024

Summary
Table Of Content

Market Insights:

Pharmacogenomics refers to the study of the human genetic make-up and corresponding tailoring of the drug treatment. Each response to the drug varies according to the genetic composition. To address such variations, genes must study how drug processing is affected by genes. Precise genetic testing helps determine targeted drug therapies and streamlines the treatment protocol to improve therapeutic results. Pharmacogenomics has various therapeutic applications, such as oncology, cardiology, pain management, neurological disorder, etc. Thus, through further advancements in this field, the goal is to shift toward preventing rather than reacting; therefore, optimizing drug therapy, enhancing drug safety, increasing patient compliance, and further reducing healthcare costs.

The “Global Pharmacogenomics Market – Growth, Future Prospects and Competitive Analysis, 2016–2024” offers strategic insights into the overall global pharmacogenomics market along with the market size and estimates for 2014 to 2024. This research study covers an in-depth analysis of multiple market segments based on the type of technology, application, and geographical distribution. The technology types studied for analyzing the overall pharmacogenomics market are categorized into microarray, sequencing, polymerase chain reaction, and other technologies. Based on applications, the pharmacogenomics market is segmented into oncology, cardiology, pain management, neurological disorders, and others.

To help strategic decision makers, the report also includes competitive profiling of the leading players in the global pharmacogenomics market and attractive investment proposition market positioning of key manufacturers sections. Market size and forecast for these regional and country-level markets are presented in this study for 2014-2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global pharmacogenomics market. Tools such as market positioning of key players and attractive investment propositions provide the readers with insights into the competitive scenario of the pharmacogenomics market. This report concludes with a company profiles section that highlights major information about the key players engaged in global pharmacogenomics market.

Based on the type of Therapeutic application, the global pharmacogenomics market is segmented as follows:

Oncology
Cardiology
Psychiatry
Infectious Diseases
Pain Management
Neurological Disorders
Others

Oncology, psychiatry, and infectious diseases are the three leading therapeutic areas that are benefited from pharmacogenomics. With the help of pharmacogenomics studies, there is a paradigm shift in respective treatments, focusing on personalized therapeutics. Oncology dominates the therapeutic applications in the pharmacogenomics market. Pharmacogenomics studies help cancer treatment by making the selective decision of the drug, by anticipating the drug response, efficacy, safety profile, toxicity within chemotherapeutic agents, and targeted immune biologics agents. Over the past few years, there has been an increase in clinical adoption of psychiatric pharmacogenomics testing. Due to the cost-effectiveness of this testing, it would be of help shortly to select psychotropic drugs and their dosing and avoid further side effects according to the patient’s need. Pharmacogenomics is being used to study the genome of both the host and pathogen. The study of the pathogen genome is used in the identification of the antigen, determining microbial resistance, and further helping in designing a vaccine. Therefore, pharmacogenomics has the potential to revolutionize the prevention, diagnosis, and treatment of infectious diseases.

Based on the type of technology, the global pharmacogenomics Market is segmented as follows:

Microarray
Sequencing
Sanger Sequencing
Pyrosequencing
Next-Generation Sequencing
Polymerase Chain Reaction
Other Technologies
Mass Spectrometry
Electrophoresis

DNA sequencing is a technique used to determine the sequence of nucleotides (Adenine, Guanine, Cytosine, and Thymine) in a particular region of DNA. With technological advancement, sequencing has gone through three generations, which include: First generation – Sanger sequencing and Gilbert sequencing; Second generation – pyrosequencing; Next generation – Illumina (Solexa). It has the ability to read DNA templates in real-time without amplification providing accurate and precise sequencing data. Thus next, generation sequencing dominates the pharmacogenomics market and is anticipated to grow further in the forecast period. PCR is another technology widely used to replicate DNA sequences in a short duration of time. Real-time PCR helps to provide comprehensive content and also helps in pharmacogenomics studies to give quick, accurate results at a lower cost. Microarray is another fast-growing technology in the field of molecular biology and genetics. DNA microarray technology is used in pharmacogenomics to search and validate new therapeutic targets and to understand the metabolic pathways, mechanism of action, and unwanted secondary effects. Finally, mass spectrometry is a high throughput technology used to detect genotyping, thus helping understand how the drug interacts with the patient. It is a quick, less expensive process used for drug monitoring. Thus, its market is anticipated to grow in the future.

For this study, the global pharmacogenomics market is geographically categorized into:

North America
Europe
Asia Pacific
Latin America (LATAM)
Middle East and Africa (MEA)

At present, North America dominates the pharmacogenomics market, followed by Europe. In developed countries, with advancements in research and development, the goal is to shift towards preventing, rather than reacting, drug therapy, enhancing drug safety, increasing patient compliance, and reducing healthcare costs. Personalized medicine emphasizes the paradigm shift in medicine from reaction to prevention. Asia Pacific is expected to be the most attractive regional global pharmacogenomics market and promises extensive growth during the forecast period. The driving factors for the market are the presence of extensive and evolved healthcare infrastructure and the increasing preference for better, cost-effective, and personalized therapeutics for various diseases and infections. In addition, there is rising R&D infrastructure and government initiatives making the region vulnerable to healthcare investments and rising research centers for personalized treatment due to the extensive population and various infections prevalent in the region.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Pharmacogenomics Market Portraiture
2.2 Global Pharmacogenomics Market Share, by Technology type, 2015 (US$ Mn)
2.3 Global Pharmacogenomics Market Share, by Application type, 2015 (US$ Mn)
2.4 Global Pharmacogenomics Market, by Geography, 2015 (Value %)

Chapter 3 Global Pharmacogenomics Market Analysis
3.1 Global Pharmacogenomics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Rise in investment in research and development
3.3.1.2 Advancement in technology pharmacogenomics engineering to create in vivo environment
3.3.2 Challenges
3.3.2.1 Lack of consistency in pharmacogenomics products
3.3.3 Opportunities
3.3.3.1 Focus on regenerative medicine
3.3.3.2 Increased awareness of organ transplantation
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key Players in Pharmacogenomics

Chapter 4 Global Pharmacogenomics Market Analysis, by Technology Type, 2014-2024 (US$ Mn)
4.1 Introduction
4.2 Microarray
4.3 Sequencing
4.3.1 Sanger Sequencing
4.3.2 Pyrosequencing
4.3.3 Next-Generation Sequencing
4.4 Polymerase Chain Reaction
4.5 Other Technologies
4.5.1 Mass Spectrometry
4.5.2 Electrophoresis

Chapter 5 Global Pharmacogenomics Market Analysis, by Application Type, 2014-2024 (US$ Mn)
5.1 Introduction
5.2 Oncology
5.3 Cardiology
5.4 Pain Management
5.5 Neurological Disorders
5.6 Other Applications

Chapter 6 Global Pharmacogenomics Market, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 7 Company Profiles
7.1 Abbott Laboratories, Inc.
7.2 Affymetrix, Inc.
7.3 AstraZeneca plc
7.4 Assurex Health
7.5 Bayer AG
7.6 GeneDX
7.7 F. Hoffmann-La Roche Ltd.
7.8 Illumina, Inc
7.9 Myriad Genetics, Inc
7.10 Merck & Co
7.11 GE Healthcare
7.12 GlaxoSmithKline
7.13 Johnson & Johnson
7.14 Pfizer, Inc.
7.15 Pathway Genomics
7.16 Qiagen, Inc.
7.17 Teva Pharmaceutical Industries Ltd
7.18 Thermo Fisher Scientific
7.19 Transgenomic, Inc.
7.20 Other Notable Players

List of Figures

FIG. 1 Global Pharmacogenomics Market: Research Methodology
FIG. 2 Global Pharmacogenomics Market Share, by Technology type, 2015 (US$ Mn)
FIG. 3 Global Pharmacogenomics Market Share, by Application type, 2015 (US$ Mn)
FIG. 4 Global Pharmacogenomics Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition: Global Pharmacogenomics Market, by Geography
FIG. 6 Market Positioning of Key Players in Pharmacogenomics
FIG. 7 Global Microarray Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 8 Global Sanger Sequencing Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 9 Global Pyrosequencing Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 10 Global Next-Generation Sequencing Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 11 Global Polymerase Chain Reaction sMarket in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 12 Global Other Technologies Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 13 Global Mass Spectrometry Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 14 Global Electrophoresis Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 15 Global Oncology Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 16 Global Cardiology Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 17 Global Pain Management Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 18 Global Neurological Disorders Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 19 Global Other Application Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)

List of Tables

TABLE 1 Global Pharmacogenomics Market, By Technology Type 2014-2024 (US$ Mn)
TABLE 2 Global Sequencing Market, By Technology Type 2014-2024 (US$ Mn)
TABLE 3 Global Pharmacogenomics Market, By Application Type 2014-2024 (US$ Mn)
TABLE 4 Global Pharmacogenomics Market, by Geography, 2014 – 2024 (US$ Mn)
TABLE 5 North America Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 6 Europe Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 7 Asia-Pacific Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 8 Latin America Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 9 Middle East and Africa Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 10 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Affymetrix, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 AstraZeneca plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Assurex Health: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 14 C Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 GeneDX: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 C B F. Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Illumina, Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Myriad Genetics, Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Merck & Co: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 GE Healthcare: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 GlaxoSmithKline: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Johnson & Johnson: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 23 Pfizer, Inc. : Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 24 Pathway Genomics : Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 25 Qiagen, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 26 Teva Pharmaceutical Industries Ltd: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 27 Thermo Fisher Scientific: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 28 Transgenomic, Inc.s: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

Frequently Asked Questions:

What is the size of Pharmacogenomics Market?

The market for Pharmacogenomics is expected to reach US$ XX Bn in 2024.

What is the Pharmacogenomics Market CAGR?

The Pharmacogenomics market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Pharmacogenomics Market?

The report is forecasted from 2016-2024.

What is the base year considered for Pharmacogenomics Market?

The base year of this report is 2015.

Who are the major players in this market?

Abbott Laboratories, Inc., Affymetrix, Inc., AstraZeneca plc, Assurex Health, Bayer AG, GeneDX, F. Hoffmann-La Roche Ltd., Illumina, Inc, Myriad Genetics, Inc, Merck & Co, GE Healthcare are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –